$34,757.35 speaking Payment -- Regeneron Pharmaceuticals to Dr. Andrew Young
Oncology Speaker Payment: Regeneron Pharmaceuticals Pays Dr. Andrew Young $34,757 for Entresto-Related Services
This page provides a detailed analysis of a $34,757.35 speaking payment from Regeneron Pharmaceuticals to Dr. Andrew Young. Data is from the CMS Open Payments (Sunshine Act) database.
Payment Details
| Field | Value |
|---|---|
| Amount | $34,757.35 |
| Payment Type | speaking |
| Payment Nature | Compensation for serving as faculty or as a speaker |
| Pharmaceutical Company | Regeneron Pharmaceuticals |
| Physician | Dr. Andrew Young |
| NPI Number | 1278634698 |
| Physician Specialty | Oncology |
| Location | Albany, NY |
| Date of Payment | 2025-01-29 |
| Related Drug/Device | Entresto |
| Conflict Assessment | Moderate -- Worth Noting |
AI-Powered Analysis of This Payment
The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.
Regeneron Pharmaceuticals made a $34.8K speaking payment to Andrew Young, a Oncology specialist in Albany, NY. The payment was associated with Entresto. The total payment of $34,757.35 to Dr. Andrew Young from Regeneron Pharmaceuticals is for speaking engagements. The payment is specifically for compensation as faculty or a speaker, indicating an educational or promotional role. The drug associated with this payment is Entresto, which is relevant to the oncology specialty.
Patient Guidance: What This Payment Means for You
If you are a patient, this payment indicates your doctor may have received compensation for educating others about Entresto, a medication used in oncology. Always discuss your treatment options with your healthcare provider and ask about alternatives.
Payment Context: Is This Amount Normal?
Payments for speaking engagements in oncology can vary widely based on the speaker's expertise, the scope of the engagement, and the pharmaceutical company's promotional activities.
Regulatory Context: Sunshine Act Requirements
This payment falls under the Sunshine Act's reporting requirements for payments made by manufacturers of drugs and medical devices to physicians and teaching hospitals.
Related Topics
This payment is related to the following healthcare transparency topics:
- speaking-fees
- speaker-compensation
- regeneron-pharmaceuticals
- oncology
- entresto
- physician-payments
Understanding speaking Payments
Speaking and education payments compensate physicians for presenting at conferences, continuing medical education (CME) events, and promotional speaking engagements. These payments often cover honoraria, preparation time, and travel expenses. Speaking fees are among the highest-value payment categories and have attracted significant attention from researchers studying potential conflicts of interest.
Frequently Asked Questions About This Payment
What was this $34.8K payment for?
This was a speaking payment of $34.8K from Regeneron Pharmaceuticals to Andrew Young, categorized as "Compensation for serving as faculty or as a speaker". It was associated with Entresto. The payment was reported under the Sunshine Act (CMS Open Payments).
Does Andrew Young accept pharmaceutical money?
Yes, Andrew Young received this $34.8K payment from Regeneron Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Andrew Young's full payment history on the CMS Open Payments database or on this site.
Is it legal for doctors to accept pharma payments?
Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.
Should I be concerned about this speaking payment?
A speaking payment of $34.8K should be evaluated in context. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.
How do I talk to my doctor about pharma relationships?
You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.
What types of pharma payments are most concerning?
Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.
Does pharma money affect what my doctor prescribes?
Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.
How does this compare to other doctors in Oncology?
To compare this payment against Oncology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Oncology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.
What does this payment reveal about Andrew Young's relationship with Regeneron Pharmaceuticals?
The payment amount is substantial, suggesting significant engagement or a series of speaking events. This $34.8K speaking payment is part of the transparency data reported under the Sunshine Act.
Is this payment amount typical for Oncology?
The payment is categorized as 'speaking,' which is a common but regulated form of industry-physician interaction.
What should patients do after learning about this payment?
If you are a patient, this payment indicates your doctor may have received compensation for educating others about Entresto, a medication used in oncology.
What else should I know about this speaking payment?
The date of payment is in the future (2025), indicating a planned engagement.
Related Reports
Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.